-+ 0.00%
-+ 0.00%
-+ 0.00%

Antengene to present preclinical Cos-TCE platform data at SITC 2026 rapid oral session

PUBT·10/03/2026 00:30:21
Listen to the news
Antengene to present preclinical Cos-TCE platform data at SITC 2026 rapid oral session
  • Antengene flagged new preclinical findings for its Cos-TCE immunotherapy platform, with results scheduled for presentation at SITC 2026.
  • The update centers on an approach designed to better control T-cell activation, aiming to improve anti-tumor activity while limiting safety liabilities.
  • Management positioned the platform readout as a pipeline catalyst as it advances multiple T-cell engager programs across oncology indications.
  • The Rapid Oral Abstract Presentation is set for Nov. 6, 2026, at the SITC annual meeting in Phoenix.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Antengene Corporation Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610022030PR_NEWS_USPR_____CN57711) on October 03, 2026, and is solely responsible for the information contained therein.